Fujirebio Holdings, Inc. and Sysmex Corp. have entered into an agreement to expand their contract development and manufacturing partnership for Sysmex’s Automated Immunoassay System HISCL-Series to include the field of neurodegenerative diseases. This follows their business collaboration in the field of immunoassay signed in October 2023.

While Fujirebio has been developing dedicated reagents for Sysmex’s HISCL-Series since 2020, the two companies agreed in October 2023 to expand their partnership, based on a common belief that combining their respective expertise in immunoassay will accelerate their global expansion and contribute to the advancement of immunoassay.

Under the new agreement in the field of neurodegenerative diseases, including Alzheimer’s Disease, Fujirebio will develop reagents for Sysmex’s HISCL-Series for cerebral spinal fluid (CSF)-based testing as well as blood-based testing. This will accelerate the expansion of Sysmex’s testing parameters in the field and its global footprint in immunoassay.